Reference: Kusminski, Christine M., et al
The current evidence does not show any inherent performance-enhancing effect of GLP-1 agonists in healthy athletes if anything, the drugs side effects and impact on muscle/fueling could impair performance
In this context, glucagon-like peptide-1 receptor (GLP-1R) agonists have been increasingly used in the treatment of pediatric obesity, with evidence supporting their efficacy in reducing body weight, BMI, and improving glycemic control, although gastrointestinal side effects, such as nausea, are common
Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic -cells
TB-500 complements these effects through its promotion of endothelial cell migration and organization
For those already on the medication, being vigilant about symptoms of gallbladder problems is essential